Name: EBV Qualitative by PCR, CSF
Test Name: EBV Qualitative by PCR, CSF
Health Link Test Code: HCCFEBV
LIS Test Code: CFEBV
CPT Code(s): 87798
Methodology: Real-Time PCR
Detect Epstein-Barr Virus (EBV) in CSF.
Days Performed: Mon-Fri.
In-Lab Turnaround Time: 2 - 3 days.
Stat In-Lab Turnaround Time: Not available stat.
Specimen: Cerebrospinal fluid (CSF)
Collection Container: Sterile screw cap container
Collection Volume: 2 mL
Pediatric Collection Volume: 2 mL
Indefinitely at -70° C.
Sample Analyzed: Cerebrospinal fluid (CSF) aliquot
Testing Volume: 2 mL
Pediatric Testing Volume: 1.2 mL
Transport specimen to Laboratory immediately. Transport on coolant pack or if frozen on dry ice.
LIMIT: One specimen every 48 hours.
Detection of low levels of EBV in specimens containing leukocytes is not unexpected, due to the ubiquitous nature of EBV infection in the population.
Interpretation Type: Expected Results
False negative results may be due to the suppression of viral replication to levels below the detection threshold, insufficient specimen collection volumes, or to inhibitory substances that may be present in the specimen. Note that low specimen collection volumes will affect the sensitivity of the lower limit of viral detection by this assay. Inadequate specimen collection, processing and storage may invalidate test results. This test should not be used as the only criterion to form a clinical conclusion, instead, results should be correlated with other test results, patient symptoms and clinical presentation. DNA sequence polymorphisms in EBV strains may result in underestimation of viral levels. The presence of variations in EBV DNA sequences are monitored in the real-time PCR assay. This assay does not genotype the virus, and consequently does not provide any information with regard to EBV drug resistance.
The performance characteristics of this test were validated by UWHC Clinical Laboratories. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA approval or clearance is currently not required for clinical use of this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. The UWHC Clinical Laboratories is authorized under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.